A phase 1/2 study of relatlimab (anti-LAG-3 monoclonal antibody) administered in combination with both nivolumab (anti-PD-1 monoclonal antibody) and BMS-986205 (IDO1 inhibitor) or in combination with both nivolumab and ipilimumab (anti-CTLA-4 monoclonal antibody) in advanced malignant tumors. Here, PDCD1 is linked to cancer.